All data that was used in this manuscript are already publicly available from the GWAS catalog (<https://www.ebi.ac.uk/gwas/>) and the STRING network (<https://string-db.org/>). All results generated from the analysis are provided in the Supporting Information tables. Scripts used in this paper are available at <https://github.com/AbhiRatnakumar/omnigenic_ppi_core_genes_plos_genetics_paper>.

Introduction {#sec001}
============

Genome-wide association studies (GWAS) have uncovered important insights into the genetic basis of complex traits. However, contrary to initial expectation, only a few large effect size-variants with mechanistic links to disease have been identified from these studies \[[@pgen.1008903.ref001]--[@pgen.1008903.ref008]\]. The omnigenic model \[[@pgen.1008903.ref009]\] attempts to resolve this paradox by viewing diseases as networks. 'Core genes' which have direct effects on pathways central to pathogenesis (e.g. synaptic genes in schizophrenia \[[@pgen.1008903.ref009]\]) are located at the center of the network, while peripheral genes contribute to disease risk via their influence on core genes. The difficulty of connecting genes within GWAS loci (GWAS hits) to mechanisms responsible for pathogenesis of disease have hindered efforts to understand disease etiologies and develop new therapies \[[@pgen.1008903.ref009],[@pgen.1008903.ref010]\].

Network inference and exome sequencing to identify deleterious, rare variants, have been proposed for identifying core genes \[[@pgen.1008903.ref009]\] directly, although these methods have limitations. For example, the sample size required for exome sequencing to identify rare variants remains uncertain \[[@pgen.1008903.ref011]\] and network inference methods require further technical development \[[@pgen.1008903.ref009]\].

An increasingly accepted view is that diseases can be thought of as perturbations to a network of genes \[[@pgen.1008903.ref012]\]. Intriguingly, functionally related proteins have been shown to reside close within the network \[[@pgen.1008903.ref012]--[@pgen.1008903.ref014]\] and a number of studies have leveraged known disease associated genes to find new candidate genes \[[@pgen.1008903.ref012]\]. For example, Markov Random Fields have been used to leverage the topology of pathways to re-prioritize GWAS hits \[[@pgen.1008903.ref015]\]. Support vector machines have been used to learn network features of GWAS hits within tissue specific networks and compute a probability of disease association in all genes \[[@pgen.1008903.ref016]\]. Finally, protein-protein interactions (PPI) with known disease genes have been used to find new disease genes \[[@pgen.1008903.ref013]\].

Although a number of prior studies have integrated GWAS data with networks \[[@pgen.1008903.ref016]--[@pgen.1008903.ref022]\], the majority of these studies tended to focus on single diseases or phenotypes \[[@pgen.1008903.ref023]--[@pgen.1008903.ref026]\]. The potential for improved insights by integrating GWAS data with protein-protein interaction networks in particular, comes from the finding, that the protein products of genes within GWAS loci physically interact with each other more than expected by chance \[[@pgen.1008903.ref027]\].

Here, we build on prior methods to combine GWAS hits with PPI networks, within the conceptual framework of the omnigenic model, to develop a 'guilt-by-protein-interaction' approach to nominate candidate core genes across a broad range of diseases and phenotypes. We hypothesize that core genes are likely to have excess protein-protein interactions with GWAS hits, and propose a method that combines GWAS hits with the STRING Protein-Protein Interaction network \[[@pgen.1008903.ref028]\], to find proteins enriched for PPI with GWAS hits. In depth examination of the proteins enriched for PPI (PPI genes) reveals properties consistent with 'core genes' as defined by the omnigenic model, and provides insight into disease biology.

Results {#sec002}
=======

We downloaded the STRING network \[[@pgen.1008903.ref028]\] and extracted physically binding protein-protein interactions with score \> = 700 (mean score 277.65, range 150--999, **[S1A Fig](#pgen.1008903.s001){ref-type="supplementary-material"}**) yielding a network with 11,049 nodes and 163,181 protein-protein interactions (**[S1 Table](#pgen.1008903.s012){ref-type="supplementary-material"}**) (Methods). We then extracted GWAS hits from the GWAS catalog \[[@pgen.1008903.ref029]\], and after performing QC and filtering for proteins present in the STRING network (11,049 nodes), identified 3,615 GWAS hits in 1,381 GWAS studies from 5 ancestries (African American or Afro-Caribbean, East Asian, European, Hispanic or Latin American and South Asian (**[Fig 1A](#pgen.1008903.g001){ref-type="fig"}, [S2 Table](#pgen.1008903.s013){ref-type="supplementary-material"}**)).

![Identifying studies with excess PPI amongst GWAS hits.\
(A) A subset of GWAS studies had excess protein-protein interactions amongst their GWAS hits. 1,381 GWAS studies were obtained from the GWAS catalog, of these 968 had at least 2 GWAS hits and 365 studies had at least 1 PPI edge between GWAS hits. Out of these 365 studies, 270 studies had more PPI edges between their GWAS hits than expected by chance. (B) (top) Schematic of our procedure for randomizing networks. We implemented the method from \[[@pgen.1008903.ref027]\]. To maintain topology, randomized networks were created by swapping labels among nodes with the same degree and swapping edges among nodes with unique degree. (bottom) Degree distribution and distribution of clustering coefficients across 50,000 randomized networks. (C) (left) Illustrative GWAS study (Breast Cancer risk, (GCST001937)) with 37 GWAS hits, and 9 PPI edges between GWAS hits. The size of each node denotes its degree, and edges between nodes indication PP interactions. (right) Results of permutation testing reveals that the observed 9 PPI edges between the 37 GWAS hits is in excess of the expected number of PPI edges obtained from 50,000 randomized networks. (D) In blue are the 365 GWAS studies with at least 1 PPI amongst their GWAS hits, in red are the 270 studies with more PPI amongst their GWAS hits than expected by chance (FDR \< 0.05).](pgen.1008903.g001){#pgen.1008903.g001}

Identifying GWAS studies with excess PPI between GWAS hits {#sec003}
----------------------------------------------------------

We first sought to extend prior work demonstrating GWAS hits have more protein-protein interactions with each other than expected by chance \[[@pgen.1008903.ref027]\]. For each GWAS study, we determined if the number of PPI edges between its GWAS hits on the STRING network exceeded the number of PPI edges between the same GWAS hits on 50,000 randomized networks (maintaining the same degree distribution and network topology of the original STRING network, (**[Fig 1B and 1C](#pgen.1008903.g001){ref-type="fig"}, [S1B Fig](#pgen.1008903.s001){ref-type="supplementary-material"}**)). Of the 1,381 GWAS studies, 365 studies had at least 2 GWAS hits and 1 PPI edge between GWAS hits (**[Fig 1A](#pgen.1008903.g001){ref-type="fig"}**). Of these 365 studies, 270 studies that had more PPI edges between GWAS hits than expected by chance (p \< 0.05) (Methods) (**[S2 Table](#pgen.1008903.s013){ref-type="supplementary-material"}**). Although PPI is related to the number of GWAS hits, studies with excess PPI were not limited to those with high numbers of GWAS hits (**[Fig 1D](#pgen.1008903.g001){ref-type="fig"}**). Importantly, studies with excess PPI did not have a significantly different number of GWAS hits (mean = 26.196) than those without excess PPI (mean = 28.663, p = 0.509, t-test) (**[S2 Fig](#pgen.1008903.s002){ref-type="supplementary-material"}).** Further, the mean degree of GWAS hits in the studies with excess PPI edges and those without was similar, 28.405 and 29.969 respectively (p = 0.117, t-test).

Since the majority of GWAS hits are in intergenic regions, and the putative causal gene is inferred by the closest location \[[@pgen.1008903.ref029]\], it is likely that this inference may often not identify the true causal gene. To demonstrate this empirically, we replaced one or all of the GWAS hits with the second closest gene to the GWAS hit and compared the proportion of studies with excess PPI to our original finding of enrichment in 74% of studies. After replacing only one of the GWAS hits in each study we found 50% of studies had excess PPI between GWAS hits, while replacing all hits with the second closest gene lead to only 21% of studies with excess PPI. Finding studies with excess PPI, even after replacing all GWAS hits indicates that in at least some cases, the second closest gene may be more likely to be the causal gene.

Detecting 'PPI Genes' in Individual GWAS studies {#sec004}
------------------------------------------------

We next sought to identify 'PPI genes', within each GWAS study by using a hyper-geometric ratio test to find nodes within the STRING network that have excess PPI to GWAS hits given the degree and the total number of GWAS hits in the study (see **[Box 1](#pgen.1008903.box001){ref-type="boxed-text"}** for definitions, **[Fig 2A and 2B](#pgen.1008903.g002){ref-type="fig"}**) (Methods). We detected 'PPI genes' in 343 of the 1,381 studies, 178 of these studies also had excess PPI among GWAS hits (**[Fig 2C](#pgen.1008903.g002){ref-type="fig"}, [S3 Table](#pgen.1008903.s014){ref-type="supplementary-material"}**). The number of 'PPI genes' detected per study ranged from 1--178 with a mean 16.227 (**[S3 Fig](#pgen.1008903.s003){ref-type="supplementary-material"}).**

### Box 1: Definitions {#sec005}

**GWAS:** *Genome-wide Association Study*

**GWAS Hit:** *Gene within genome-wide significant loci (p\<5x10*^*-8*^*)*

**PPI:** *Protein-Protein Interaction*

**Core Gene:** *Gene with direct role in disease*

**Candidate Core Gene\*:** *Genes identified by our method that are likely to be core genes*

**PPI gene\***: *Gene with excess PPI with GWAS hits*. *Can be PPI only or PPI-GWAS*. *We demonstrate in the manuscript that PPI genes are candidate core genes*

**PPI only:** *PPI genes that are not GWAS hits*

**PPI-GWAS:** *PPI genes that are also GWAS hits*

**GWAS only:** *GWAS hits that are not PPI genes*

***ALL***: *All 11,049 genes within the STRING network*

**Somatically Mutated PPI genes:** *Genes with excess PPI with somatically mutated cancer genes*. *Can be PPI only or PPI-Somatically Mutated*. *We demonstrate in the manuscript that PPI genes predicted from somatically mutated cancer genes are candidate core genes*.

**PPI-Somatically Mutated:** *PPI genes predicted from somatically mutated cancer genes*, *that are also somatically mutated cancer genes themselves*

**Somatically Mutated:** *Somatically mutated cancer genes that are not PPI genes*

**\*PPI gene** *and* **Candidate core gene** *mean the same thing and are used interchangeably through out the text*. *Our method detects* **PPI genes**, *and since* **PPI genes** *are enriched for disease relevance*, *Clinvar pathogenic variants and drug targets*, *we argue that* **PPI genes** *are also* **candidate core genes.**

![Identifying 'PPI genes' using nearest neighbor GWAS hits.\
(A) This figure was adapted from \[[@pgen.1008903.ref030]\] ([Creative Commons CC-BY](http://creativecommons.org/licenses/by/4.0/) license), it illustrates our method for detecting PPI genes. This method involves putting GWAS hits from the GWAS catalog onto the STRING PPI network, and identifying neighboring nodes that have excess PPI with the GWAS hits. We also define the following terms. 'GWAS': Genome-wide Association Study, 'GWAS HIT' Gene within genome-wide significant loci (p \< 5x10^-8^), 'PPI': Protein-Protein Interaction. 'CORE GENE': Gene with direct roles in disease biology 'CANDIDATE CORE GENE': Gene identified by our method that is likely to be a core gene. 'PPI Gene': PPI only or PPI-GWAS gene, 'GWAS ONLY': GWAS hit that is not a PPI gene. 'PPI-GWAS': PPI gene that is also a GWAS hit. 'PPI only': PPI gene that is not a GWAS hit. 'All': all 11,049 nodes within the STRING network. (B) Schematic demonstrating how we detected PPI genes in 343 Individual GWAS studies (178 of these studies had excess PPI between GWAS hits, while 165 studies did not show excess PPI among GWAS hits). (C) Proportion of studies with excess PPI that we also detect PPI genes in. Out of 270 studies in which we detect excess PPI amongst GWAS hits, we detect PPI genes in 178 studies. Amongst the remaining 1,111 GWAS studies, we detect PPI genes in 165 studies.](pgen.1008903.g002){#pgen.1008903.g002}

Strikingly, we found that many of the PPI genes had strong disease relevance (**[Table 1](#pgen.1008903.t001){ref-type="table"}**). For instance, we detected *BRCA1* \[[@pgen.1008903.ref031]--[@pgen.1008903.ref034]\] in Breast Cancer **([Table 1](#pgen.1008903.t001){ref-type="table"}, [Fig 3A](#pgen.1008903.g003){ref-type="fig"}, [S4 Fig](#pgen.1008903.s004){ref-type="supplementary-material"}, [S3 Table](#pgen.1008903.s014){ref-type="supplementary-material"})**, Amyloid Precursor Protein (*APP*) in Alzheimer's Disease \[[@pgen.1008903.ref035]--[@pgen.1008903.ref037]\], *INS* in A1C measurement and Type 2 Diabetes, *PCSK9* in LDL cholesterol levels \[[@pgen.1008903.ref038],[@pgen.1008903.ref039]\] and *SNCAIP* \[[@pgen.1008903.ref040],[@pgen.1008903.ref041]\] in Parkinson's Disease, and the circadian rhythm gene *CRY2* in Morning vs. Evening chronotype \[[@pgen.1008903.ref042]\].

![PPI gene examples.\
(A) Representative examples of PPI genes predicted by our method. The lines between nodes represent PPI, and the GWAS hits are depicted as pointing to PPI genes. The corresponding GWAS catalog study accessions are shown within parentheses. (B) Proportion of PPI genes within the 343 studies that we detect PPI genes in that are PPI only compared to PPI-GWAS. (C) Proportion of Clinvar pathogenic variant containing genes in All 11,049 nodes, GWAS only, PPI only and PPI-GWAS. We found enrichment in PPI only compared to GWAS only (p \< 0.0047, Fisher's Exact Test) and in PPI-GWAS compared to GWAS only (p \< 1.092x10^-7^, Fisher's Exact Test). (D) Out of 343 GWAS studies in which we detected PPI genes, 99 had at least 1 PPI-GWAS. We ranked the GWAS hits within each study by the GWAS p-value, and then computed rank fractions (rank/number of GWAS hits in the study). In gray is the distribution of rank fractions, across all GWAS hits from the 99 studies, in red is the distribution of rank fractions amongst only the PPI-GWAS. The PPI-GWAS distribution is skewed to the left indicating that PPI-GWAS tend to have more significant p-values compared to GWAS only. (E) In black are the ranks of all GWAS hits in the 99 GWAS studies, and in red are the ranks of only the PPI-GWAS. PPI-GWAS tend to cluster towards the left of the plot, indicating that PPI-GWAS tend to have more significant GWAS p-values.](pgen.1008903.g003){#pgen.1008903.g003}

10.1371/journal.pgen.1008903.t001

###### Examples of PPI genes.

![](pgen.1008903.t001){#pgen.1008903.t001g}

  ------------------------------------------------------------------------------------------------------------------------
  PPI Gene   Study accession   P-value   Rank of p-value   GWAS hit   Study with rare variant
  ---------- ----------------- --------- ----------------- ---------- ----------------------------------------------------
  *BRCA1*    GCST001937\       0.026     2/21              no         \[[@pgen.1008903.ref031]--[@pgen.1008903.ref034]\]

  *INS*      GCST001213        0.017     1/1               no         \[[@pgen.1008903.ref043]\]

  *APP*      GCST002245        0.039     27/28             no         \[[@pgen.1008903.ref035]--[@pgen.1008903.ref037]\]

  *PCSK9*    GCST000282        0.001     6/77              no         \[[@pgen.1008903.ref038],[@pgen.1008903.ref039]\]

  *SNCAIP*   GCST002544        0.011     1/1               no         \[[@pgen.1008903.ref040],[@pgen.1008903.ref041]\]

  *LPL*      GCST000132        0.001     7/83              no         \[[@pgen.1008903.ref044]\]
  ------------------------------------------------------------------------------------------------------------------------

Because our method surveys each node in the STRING network in an unbiased way, it is possible for GWAS hits to also be PPI genes themselves. To better understand differences between these classes of PPI genes, we termed 'PPI genes' that also are GWAS hits as 'PPI-GWAS', while 'PPI genes' that are not GWAS hits are 'PPI only', and GWAS hits that are not 'PPI genes' are "GWAS only" (see also **[Box 1](#pgen.1008903.box001){ref-type="boxed-text"}**). Surprisingly, there were many more PPI only (n = 1,821) compared to PPI-GWAS (n = 172) across the individual GWAS studies (**[Fig 3B](#pgen.1008903.g003){ref-type="fig"}**). Suggesting that most 'PPI genes' are not detected by GWAS alone.

Clinvar enrichment: PPI genes are candidate core genes {#sec006}
------------------------------------------------------

The omnigenic model proposes that core genes are central to disease pathogenesis, and can be detected by deep sequencing to identify deleterious, rare variants \[[@pgen.1008903.ref009]\]. We hypothesized that if our PPI genes are enriched for Clinvar pathogenic variants, that would suggest they are good candidates for core genes as described by the omnigenic model. We looked for overlaps between our PPI genes and genes with pathogenic variants within Clinvar \[[@pgen.1008903.ref045]\] (**[Fig 3C](#pgen.1008903.g003){ref-type="fig"}, [S4 Table](#pgen.1008903.s015){ref-type="supplementary-material"}**), and found a higher proportion of Clinvar pathogenic variants in PPI only compared to GWAS only (33% vs. 29% respectively, p \< 0.0047, **[Fig 3C](#pgen.1008903.g003){ref-type="fig"}**) and PPI-GWAS compared to GWAS only (49% vs. 29%, p \< 1.092x10^-7^). We found that this enrichment remained, even after correcting for node degree (**[S5 Fig](#pgen.1008903.s005){ref-type="supplementary-material"}**). Suggesting that the PPI genes we detect are candidate core genes.

Enriched Disease association: PPI genes are candidate core genes {#sec007}
----------------------------------------------------------------

The omnigenic model also suggests that core genes are likely to be more disease associated \[[@pgen.1008903.ref009]\]. We hypothesized that if the PPI-GWAS identify more disease relevant GWAS loci, these may have stronger GWAS p-values than GWAS hits that are not PPI genes (GWAS only). To test this, we extracted GWAS p-values for each GWAS hit from the GWAS catalog. Then compared the relative rankings of PPI-GWAS and GWAS only p-values within each study, and computed a 'rank fraction', where the p-value rank (lower p-values associated with lower ranks) is divided by the total number of GWAS hits in the study (**[S5 Table](#pgen.1008903.s016){ref-type="supplementary-material"}**). Of the 343 GWAS studies with PPI genes, 99 contained at least 1 PPI-GWAS. Within these 99 GWAS studies we found that PPI-GWAS tended to have lower ranks and more significant p-values compared to GWAS only (**[Fig 3D and 3E](#pgen.1008903.g003){ref-type="fig"}**). For example, 42% of PPI-GWAS were ranked in the top 25% of P-values (p \< 1.638x10^-11^) while 17% were ranked in the top 10% (p \< 2.333x10^-5^) (**[S5 Table](#pgen.1008903.s016){ref-type="supplementary-material"}**). This enriched disease association of PPI-GWAS compared to GWAS only, suggests that PPI genes are candidate core genes.

Detecting PPI genes in overarching disease processes (Parent Terms) {#sec008}
-------------------------------------------------------------------

We subsequently sought to identify PPI genes in overarching disease processes. Conveniently, the GWAS catalog annotates related GWAS studies with a parent term. For instance, cancer related GWAS studies are grouped under the \'Cancer\' parent term, and neurologically related GWAS studies are grouped under the 'Neurological Disorders' parent term. In order to detect PPI genes in over-arching diseases processes, we merged GWAS hits from GWAS studies with the same GWAS catalog \[[@pgen.1008903.ref029]\] provided parent term.

Similar to our analysis of individual GWAS studies, we first sought to identify parent terms with excess PPI edges between GWAS hits, and compared PPI edges in GWAS studies aggregated by parent term against a similar analysis across 50,000 randomized networks (controlled for degree distribution and network topology). We found that 16 of 17 parent terms had excess PPI between GWAS hits (**[Fig 4A](#pgen.1008903.g004){ref-type="fig"}**), and the only parent term without excess PPI was 'Liver Enzyme Measurement'. To detect PPI genes, we applied the same hyper-geometric ratio test based method described above (Methods) to the merged GWAS hits from each parent term. Our method detected PPI genes in 12 parent terms (mean of 73.1, range: 5--255, **[S6 Table](#pgen.1008903.s017){ref-type="supplementary-material"}**, **[S3 Fig](#pgen.1008903.s003){ref-type="supplementary-material"}**). The parent terms we do not detect PPI genes in are 'Response to Drug', 'Other Trait', 'Metabolic Disorder' and 'Body Measurement'.

![PPI genes in Parent Terms.\
(A) Each study in the GWAS catalog is annotated with parent terms. In order to find PPI genes amongst parent terms, we merged GWAS hits from different GWAS studies with the same parent term. We first looked for evidence of excess PPI among parent term GWAS hits. Out of 17 parent terms, we found excess PPI among GWAS hits within 16 parent terms and detected PPI genes in 12 parent terms. (B) The proportion of PPI genes in each parent term that is PPI only vs. PPI-GWAS. The 'Lipid and Lipoprotein Measurement' parent term had the largest proportion of PPI-GWAS. (We excluded the parent terms 'Biological Process', 'Other Measurement' and 'Other Disease' due to vagueness). (C) Proportion of Clinvar pathogenic variant containing genes in All 11,049 nodes, GWAS only, PPI only and PPI-GWAS. We found enrichment in PPI only compared to GWAS only (p \< 8.015x10^-6^, Fisher's Exact Test) and in PPI-GWAS compared to GWAS only (p \< 0.004, Fisher's Exact Test). (D) Overlap of cancer parent term PPI genes with COSMIC, ONCOKB or Therapeutic Targets Database genes respectively. The numbers on top of each bar correspond to the number of PPI genes that overlaps with the genes from that gene category. COSMIC: Cancer Parent Term PPI genes were compared to the COSMIC cancer gene census germline genes \[[@pgen.1008903.ref052]\]. Compared to GWAS only, we found that PPI-GWAS (p \< 0.002, Fisher's Exact Test) and PPI-only (p \< 8.153x10^-5^, Fisher's Exact Test) were enriched for overlaps. ONCOKB: Cancer drug targets were obtained from Oncokb \[[@pgen.1008903.ref053]\] and we found enrichment in PPI-GWAS (p \< 0.006) compared to GWAS only. TTD: Cancer drug targets were obtained from the Therapeutic Targets Database \[[@pgen.1008903.ref054]\] (Methods), and we found enrichment in PPI-GWAS (p \< 0.025, Fisher's Exact Test) compared to GWAS only.](pgen.1008903.g004){#pgen.1008903.g004}

Again, we found striking disease relevance (**[S6 Table](#pgen.1008903.s017){ref-type="supplementary-material"})**. For instance, we found *PALB2* in Cancer \[[@pgen.1008903.ref046],[@pgen.1008903.ref047]\], *JAK-STAT* pathway in 'Digestive System Disorder' \[[@pgen.1008903.ref048],[@pgen.1008903.ref049]\] and *LPL* (Lipoprotein Lipase) in 'Lipid or Lipoprotein Measurement' \[[@pgen.1008903.ref047],[@pgen.1008903.ref050],[@pgen.1008903.ref051]\]. Consistent with the omnigenic prediction that core genes have deleterious rare variants, is prior analysis of UK biobank data. Which found protein truncating variants \[[@pgen.1008903.ref047]\] in *PALB2* associated with breast cancer diagnosis and a family history of breast cancer, and protein truncating variants in *LPL* associated with decreased risk for high cholesterol \[[@pgen.1008903.ref047]\].

Similar to our analysis of individual GWAS studies, there were many more PPI only (n = 459 unique candidate core genes) compared to PPI-GWAS (n = 194) across parent terms (**[Fig 4B](#pgen.1008903.g004){ref-type="fig"}**). Comparison of PPI gene proportions across parent terms revealed 'Lipid or Lipoprotein Measurement' had the highest proportion (41%) of PPI-GWAS (**[Fig 4B](#pgen.1008903.g004){ref-type="fig"}, [S7 Table](#pgen.1008903.s018){ref-type="supplementary-material"}**), suggesting that lipid trait GWAS are better able to uncover PPI genes.

Clinvar enrichment: Parent Term PPI genes are candidate core genes {#sec009}
------------------------------------------------------------------

Lastly, we explored the overlap between parent term PPI genes and genes containing pathogenic variants within Clinvar\[[@pgen.1008903.ref045]\] (**[Fig 4C](#pgen.1008903.g004){ref-type="fig"}, [S4 Table](#pgen.1008903.s015){ref-type="supplementary-material"}**). We found a higher proportion of Clinvar pathogenic variants in PPI only compared to GWAS only (39% vs. 28%, p \< 8.015x10^-6^) (**[Fig 4C](#pgen.1008903.g004){ref-type="fig"}**), and between PPI-GWAS and GWAS only (38% vs. 28%, p \< 0.004). Interestingly, the PPI only genes from the parent term analysis identified a stronger association with Clinvar pathogenic variants compared to the PPI only genes from the individual GWAS studies (39% vs. 33%, p \< 0.015, **[Fig 3C](#pgen.1008903.g003){ref-type="fig"}**), suggesting that the parent term analysis might have more power to detect PPI genes. To ensure that the Clinvar pathogenic variant containing genes that overlap with our parent term PPI genes are disease relevant, we also performed pathway enrichment analysis (Methods), and identified clearly disease relevant pathways in parent terms (**[S8 Table](#pgen.1008903.s019){ref-type="supplementary-material"}**). Our finding of enrichment for Clinvar pathogenic variants amongst parent term PPI genes suggests that parent term PPI genes are candidate core genes.

Enriched disease relevance: Parent Term PPI genes are candidate core genes {#sec010}
--------------------------------------------------------------------------

We next investigated the Cancer parent term PPI genes in further detail. The Cancer parent term contained 403 GWAS hits merged from 142 cancer GWAS studies from various types of cancer (**[S9 Table](#pgen.1008903.s020){ref-type="supplementary-material"}**), and from these we identified 109 cancer parent term PPI genes (78 PPI only, 31 PPI-GWAS (**[S6 Fig](#pgen.1008903.s006){ref-type="supplementary-material"}**)). Pathway enrichment analysis revealed that these 78 PPI only were enriched for DNA repair pathways (**[S10 Table](#pgen.1008903.s021){ref-type="supplementary-material"}**) amongst others.

Since cancer involves both germline predisposition involving rare variants as well as somatic acquisition of mutations in critical genes, we sought to determine how our germline identified PPI genes compared with known cancer driver gene lists, such as the COSMIC cancer gene census \[[@pgen.1008903.ref052]\]. Comparison of the COSMIC germline cancer gene census (n = 95) (**[S11 Table](#pgen.1008903.s022){ref-type="supplementary-material"}**), revealed preferential enrichment for PPI only to GWAS only (14% vs. 2.4%, p \< 8.153x10^-5^) and PPI-GWAS to GWAS only (16% vs. 2.4%, p \< 0.002) (**[Fig 4D](#pgen.1008903.g004){ref-type="fig"}**). This pattern held up even after correcting for node degree (**[S7 Fig](#pgen.1008903.s007){ref-type="supplementary-material"}**).

Drug Target Enrichment: Parent Term PPI genes are candidate core genes {#sec011}
----------------------------------------------------------------------

To investigate whether Cancer PPI genes are enriched for drug targets. We obtained cancer drug targets from Oncokb (n = 52) \[[@pgen.1008903.ref053]\] (**[S12 Table](#pgen.1008903.s023){ref-type="supplementary-material"}**), and found enrichment in PPI-GWAS compared to GWAS only (13% vs. 2%, p \< 0.006, **[Fig 4D](#pgen.1008903.g004){ref-type="fig"}**). For confirmation, we also performed a similar analysis using the 207 cancer drug targets obtained from the Therapeutic Target Database \[[@pgen.1008903.ref054]\] (**[S13 Table](#pgen.1008903.s024){ref-type="supplementary-material"}**)(Methods) and found similar results (**[Fig 4D](#pgen.1008903.g004){ref-type="fig"}**). PPI-GWAS was enriched compared to GWAS only (13% vs. 3.1%, p \< 0.025). Importantly these patterns held up even after correcting for node degree (**[S7 Fig](#pgen.1008903.s007){ref-type="supplementary-material"}**).

Detecting PPI genes from Somatically Mutated cancer genes {#sec012}
---------------------------------------------------------

We hypothesized that our method may also work on disease-associated genes obtained from methods other than GWAS, such as genes enriched for somatic mutations in tumors. We obtained genes enriched for somatic mutations across 21 tumor types \[[@pgen.1008903.ref055]\] and after filtering for those within our list of 11,049 genes (**[S1 Table](#pgen.1008903.s012){ref-type="supplementary-material"}**), found 218 somatically mutated cancer genes (**[S14 Table](#pgen.1008903.s025){ref-type="supplementary-material"}**).

To determine whether these 218 somatically mutated cancer genes have more PPI edges with each other than expected by chance, we counted the number of PPI edges between the 218 somatically mutated cancer genes on the STRING network and compared this to the number of PPI edges between the same somatically mutated cancer genes across 50,000 randomized networks (maintaining degree distribution and network topology). In the STRING network we observed 495 PPI edges between the 218 somatically mutated cancer genes while the largest number of PPI edges between the same 218 somatically cancer genes in any of the other randomized networks was only 366, suggesting that somatically mutated cancer genes have more PPI with each other than expected by chance (**[Fig 5A](#pgen.1008903.g005){ref-type="fig"}**, **[S8 Fig](#pgen.1008903.s008){ref-type="supplementary-material"}**).

![PPI Genes identified from Somatically mutated Cancer Genes.\
**(**A) Schematic showing how we assessed 218 somatically mutated cancer genes for excess PPI, and then used them to predict PPI genes. 'PPI-Somatically Mutated': PPI genes predicted from somatically mutated cancer genes, that are also somatically mutated cancer genes themselves. 'Somatically Mutated': Somatically mutated genes that are not PPI genes. 'PPI only': PPI genes that are not in the list of 218 somatically mutated genes 'All': all 11,049 nodes in the network. (B) We detected 843 PPI genes from the somatically mutated cancer genes, 742 were PPI only while 101 were PPI-Somatically Mutated. (C) Amongst the PPI genes we predicted from the somatically mutated genes, ranked 2^nd^ was *TP53*. *TP53* has a degree of 284 and has PPI with 31 of the 218 somatically mutated genes. *TP53* is shown in cyan, and in yellow are the 31 somatically mutated cancer genes that have PPI with *TP53*. The PPI edges are represented as lines. (D) To better understand the relationship between node degree and the number of PPI edges to the 218 somatically mutated genes, we took each node in the network (n = 11,049) and counted the number of PPI edges to the 218 somatically mutated cancer genes. We plotted the number of PPI edges of each node compared to the degree of the node and show PPI genes in red, and highlight *TP53* with an asterisk. (E) Overlap of somatically mutated PPI genes with COSMIC, ONCOKB or Therapeutic Targets Database genes respectively. The numbers on top of each bar correspond to the number of PPI genes that overlaps with the genes from that gene category. COSMIC: Somatically mutated genes and PPI genes were split into PPI-only, PPI-Somatically Mutated, Somatically Mutated and All (see **[Box 1](#pgen.1008903.box001){ref-type="boxed-text"}** for definitions). Then each category was compared to the COSMIC cancer gene census somatic genes \[[@pgen.1008903.ref052]\]. We found that PPI-Somatically mutated (p \< 0.001, Fisher's Exact Test) was enriched compared to Somatically mutated. ONCOKB: Comparison to cancer drug targets from Oncokb \[[@pgen.1008903.ref053]\], revealed PPI-Somatically mutated was enriched compared to Somatically mutated (p \< 0.001, Fisher's Exact Test).](pgen.1008903.g005){#pgen.1008903.g005}

To detect PPI genes from these 218 somatically mutated cancer genes, we implemented the same method described above, but instead of GWAS hits we used 218 somatically mutated cancer genes (**[S14 Table](#pgen.1008903.s025){ref-type="supplementary-material"}**), and detected 843 PPI genes (**[S15 Table](#pgen.1008903.s026){ref-type="supplementary-material"})** (we refer to these as somatically mutated PPI genes, see **[Box 1](#pgen.1008903.box001){ref-type="boxed-text"}**). When we compared these 843 somatically mutated PPI genes to the 218 somatically mutated cancer genes themselves, we found an overlap of 101 (we refer to these as 'PPI-Somatically Mutated'), which means that 742 of the somatically mutated PPI genes represent novel associations (we refer to these as 'PPI only', see **[Box 1](#pgen.1008903.box001){ref-type="boxed-text"}**, **[S15 Table](#pgen.1008903.s026){ref-type="supplementary-material"}**). Indicating that similar to the individual GWAS studies (**[Fig 3B](#pgen.1008903.g003){ref-type="fig"}, [S3 Table](#pgen.1008903.s014){ref-type="supplementary-material"}**) and parent term analysis (**[Fig 4B](#pgen.1008903.g004){ref-type="fig"}, [S6 Table](#pgen.1008903.s017){ref-type="supplementary-material"}**), there are many more PPI only compared to PPI-Somatically Mutated (**[Fig 5B](#pgen.1008903.g005){ref-type="fig"}**). Intriguingly out of 843 somatically mutated candidate core genes (**[S15 Table](#pgen.1008903.s026){ref-type="supplementary-material"}**) ranked second with p \< 1.3x10^-11^ was *TP53*, *TP53* has a degree of 284 and was found to have PPI with 31 of the 218 somatically mutated genes (**[Fig 5C](#pgen.1008903.g005){ref-type="fig"}, [S15 Table](#pgen.1008903.s026){ref-type="supplementary-material"}**).

We also compared degree distributions and found that PPI genes tended to have higher degree (**[S9 Fig](#pgen.1008903.s009){ref-type="supplementary-material"}**).To better understand the relationship between node degree and number of PPI edges with the 218 somatically mutated cancer genes, we plotted the number of PPI edges between every node in the network and the node degree (**[Fig 5D](#pgen.1008903.g005){ref-type="fig"}),** and found that although higher degree nodes have more PPI edges, PPI genes have more PPI edges than expected given their degree. To further illustrate that the PPI genes signal is not driven by node degree, we also computed the proportion of somatically mutated PPI genes within degree bins (**[S10 Fig](#pgen.1008903.s010){ref-type="supplementary-material"}**), and found little evidence that PPI genes were driven by higher degree nodes.

Enriched disease relevance: Somatically Mutated PPI genes are candidate core genes {#sec013}
----------------------------------------------------------------------------------

Interestingly our method detected *TP53* to be ranked second amongst all somatically mutated PPI genes. *TP53* was in our list of 'PPI-Somatically Mutated' (**[S15 Table](#pgen.1008903.s026){ref-type="supplementary-material"}**), because in addition to being a PPI gene, it was also a somatically mutated cancer gene itself (**[S14 Table](#pgen.1008903.s025){ref-type="supplementary-material"}**). This finding suggests that in addition to being somatically mutated in cancer, *TP53* may also act like a "hub" or "master-regulator" for other Somatically Mutated genes. Ranked first amongst the somatically mutated PPI genes was *CTNBB1* (p \< 1.12 x 10−^15^) which is also well known in cancer pathogenesis (**[S15 Table](#pgen.1008903.s026){ref-type="supplementary-material"}**). The strong disease relevance of *TP53* and *CTNBB1* within the context of cancer, suggests that the PPI genes we detect from the somatically mutated cancer genes are candidate core genes.

To further assess disease relevance, we compared the COSMIC cancer gene census \[[@pgen.1008903.ref052]\] somatic genes (n = 472) (**[S16 Table](#pgen.1008903.s027){ref-type="supplementary-material"}**) to our candidate core genes from the somatically mutated analysis, and found enrichment amongst PPI-Somatically Mutated compared to Somatically Mutated (61% vs. 39%, p \< 0 .001) (**[Fig 5E](#pgen.1008903.g005){ref-type="fig"}**). This pattern remained even after node degree correction (**[S11 Fig](#pgen.1008903.s011){ref-type="supplementary-material"}**).

Drug Target Enrichment: Somatically Mutated PPI genes are candidate core genes {#sec014}
------------------------------------------------------------------------------

We also compared the PPI genes we detected from the somatically mutated analysis to Oncokb \[[@pgen.1008903.ref053]\] drug targets (n = 52) (**[S12 Table](#pgen.1008903.s023){ref-type="supplementary-material"}**) and found that PPI-Somatically Mutated was enriched compared to Somatically Mutated (24% vs. 7% p \< 0.001) (**[Fig 5E](#pgen.1008903.g005){ref-type="fig"}**), even after correcting for node degree (**[S11 Fig](#pgen.1008903.s011){ref-type="supplementary-material"}**), suggesting that the somatically mutated PPI genes we detect are candidate core genes.

Comparison across different interaction types in STRING Network {#sec015}
---------------------------------------------------------------

The method we have proposed here, could in theory be applied to any network. We've applied it to the STRING network's physically binding (mode = "binding") PP interaction network due to prior evidence that GWAS hits physically interact with each other more than expected by chance \[[@pgen.1008903.ref027]\]. However, there are 6 other interaction types captured within the STRING network (mode = "reaction/catalysis/activation/inhibition/ptmod(post-translational modification)/expression"), and the STRING network contains a number of experimental assays, one of which is coexpression. In order to assess the performance of our method across different interaction types, we built PPI networks on the 6 other interaction types and for co-expression(Methods).

In order to facilitate comparison, we used the 403 cancer parent term GWAS hits to detect PPI genes across the 8 networks **([S17 Table](#pgen.1008903.s028){ref-type="supplementary-material"}**), and filtered each network for the 11,049 nodes from our physically binding network. To assess performance, we counted the number of PPI genes, checked whether *TP53* was detected, and whether there was enrichment for Clinvar pathogenic variants and for cancer drug targets from Oncokb \[[@pgen.1008903.ref053]\]. Comparison across 8 different networks revealed that the physically binding network (mode = "binding") described in this manuscript outperformed the other networks (**[Table 2](#pgen.1008903.t002){ref-type="table"}**), however this might be due to this network having more nodes.

10.1371/journal.pgen.1008903.t002

###### Comparison of our method applied to networks built with different interaction types.

![](pgen.1008903.t002){#pgen.1008903.t002g}

  Type                              \# nodes   \# PPI genes   Is *TP53* a PPI gene?   Clinvar    Oncokb
  --------------------------------- ---------- -------------- ----------------------- ---------- ----------
  Reaction                          5583       116            no                                 
  Binding                           11,049     109            yes                     enriched   enriched
  Catalysis                         5,277      21             no                                 
  Activation                        5,229      35             yes                     enriched   
  Inhibition                        2,802      3              no                                 
  Post-translational Modification   2,566      8              no                                 enriched
  Expression                        1,460      55             no                                 enriched
  Co-expression                     8,231      167            yes                                

Discussion {#sec016}
==========

By combining GWAS hits with PPI networks, we have developed a method for detecting 'PPI genes', and after detailed characterization found that these PPI genes are enriched for disease relevance, Clinvar pathogenic variants and drug targets--suggesting they are candidate 'core genes' as defined by the omnigenic model \[[@pgen.1008903.ref009]\]. We applied our method to 1,381 GWAS studies, and detected candidate core genes in 343 individual GWAS studies, 12 overarching parent terms, and somatically mutated cancer genes.

We demonstrate that GWAS hits that are also candidate core genes (i.e. PPI-GWAS), are more strongly statistically associated with the underlying trait than those loci that are not candidate core genes (i.e. GWAS only). In addition, we demonstrate that many candidate core genes have no excess GWAS signal (PPI only)---suggesting that they are unlikely to be detected in GWAS of larger sample size. We present a new application of GWAS data: identifying core genes as envisioned by the omnigenic model that do not themselves exhibit GWAS signal by consulting physical interactions. Our results provide unique insights into disease biology and suggest that GWAS can be combined with PPI networks to detect "core genes".

Our method was able to uncover novel insights into cancer, these include detecting 109 candidate core genes from germline GWAS hits and 843 candidate core genes from genes enriched for somatic mutations in tumors \[[@pgen.1008903.ref055]\]. We also found that somatically mutated cancer genes are connected to each other with excess PPI, suggesting an underlying biological process such as a protein complex unifying the seemingly disparate somatically mutated cancer genes. In addition, we found *TP53* to be a highly statistically significant PPI-Somatically Mutated candidate core gene, suggesting that in addition to being somatically mutated itself, it may also be a regulator of other somatically mutated cancer genes.

Although the omnigenic model is usually described in terms of gene-regulatory networks \[[@pgen.1008903.ref009]\], it is just as plausible for peripheral gene effects to be mediated by PPI as it is for them to be mediated by gene-regulatory networks. An important implication of our work, is that it suggests that GWAS hits are more important, than is currently captured by the omnigenic model \[[@pgen.1008903.ref009]\]. Adding an additional tier comprising of GWAS hits, such that core genes are at the center, followed by GWAS hits, then peripheral genes expressed in the right cell type, followed by all other genes might better capture the importance of GWAS hits.

Although our data and results are compelling, some caveats and limitations remain. Firstly, we obtained GWAS hits from the GWAS catalog \[[@pgen.1008903.ref029]\], rather than summary statistics, which could introduce heterogeneity in terms of methods and sample sizes used by different research groups. However, we attempted to mitigate this by only considering loci within the stringent genome-wide significance p-value threshold (5x10^-8^). Another potential limitation is that we assume GWAS hits are correctly associated with causal variants, and that non-coding variants, are linked to the correct gene. The GWAS catalog \[[@pgen.1008903.ref029]\] lists genes reported in the literature, and also uses an automated pipeline to map the gene closest to the most associated SNP in each loci. This is in line with what is known about causal genes \[[@pgen.1008903.ref027]\], however it's difficult to know whether the annotated genes are causal. We tested this empirically and found that although the second closest gene is likely to be causal in some cases, the proportion of studies with excess PPI is highest with the first closest gene. In addition, to further mitigate this risk, we limited our analysis to loci annotated with only 1 or 2 genes within the GWAS catalog. Another limitation might be that the Clinvar enrichment at PPI-GWAS compared to GWAS only, could be due to the PPI-GWAS gene being the actual causal rather than the GWAS only gene. Although it is difficult to rule out this possibility, our finding that replacing GWAS hits with the second closest gene results in a lower proportion of studies with excess PPI edges, indicates that the GWAS hits are likely to be the causal gene in a number of studies.

In our parent term analysis we attempted to predict candidate core genes by combining studies with related traits. However, these studies may not be independent, in addition, the different disease studies may not be equally represented. For instance, in the cancer parent term, breast and prostate cancer studies were more highly represented (**[S9 Table](#pgen.1008903.s020){ref-type="supplementary-material"}**), suggesting that the cancer core genes may be biased towards these cancer types.

We suggest that, future work may involve using other methods to validate our candidate core gene predictions, using deep sequencing to identify rare, deleterious variants and wet lab experiments to validate disease relevance. In addition, applying our methods to tissue and cell-type specific PPI networks is likely to increase accuracy, by leveraging disease specific PP interactions that may not be present in the current network.

We have presented here, a simple, yet powerful method for detecting candidate core genes, by intersecting GWAS hits with human protein-protein interactions. The significance of this, is that even if most core genes cannot be detected by GWAS directly, intersecting with predefined PPI networks enables GWAS hits to be used as a hook to uncover core genes in a 'guilt by protein interaction' approach. Our approach adds another layer to interpreting GWAS signal.

Methods {#sec017}
=======

Protein-protein interaction network {#sec018}
-----------------------------------

We downloaded the files 9606.protein.links.v10.5.txt, 9606.protein.actions.v10.5.txt and protein.aliases.v10.5.txt from version 10.5 of the STRING PPI network \[[@pgen.1008903.ref056]\] ([https://STRING-db.org/cgi/download.pl?sessionId=x8qiRTBCS4ps](https://string-db.org/cgi/download.pl?sessionId=x8qiRTBCS4ps)). The 9606.protein.links.v10.5.txt file contains scored links between proteins, the 9606.protein.actions.v10.5.txt file contains interaction types and the protein.aliases.v10.5.txt contains aliases for STRING proteins.

In order to maintain standard nomenclature for gene names, we also downloaded the HGNC gene database, by navigating to the Downloads page from the HGNC website <https://www.genenames.org/cgi-bin/statistics>, and downloading the text file, which contained 19,198 protein products per loci group. We used custom scripts to convert the Ensembl gene ids from STRING, into gene aliases (using protein.aliases.v10.5.txt), and then converted these aliases to current approved gene HGNC symbols. We used the 9606.protein.links.v10.5.txt file to extract the protein links, and in order to filter for physically binding PP interactions, we then navigated to the file 9606.protein.actions.v10.5.txt, and used the third column entitled 'mode' and filtered for entries containing the term 'binding'. We know these refer to physical PP interactions as the FAQ section of the STRING database website ([http://version10.STRING-db.org/help/faq/](http://version10.string-db.org/help/faq/)), states "*In order to get the physical interactions you need to download proteins*.*actions*.*(version)*.*txt*.*gz from download section*. *If the interaction is marked as \"binding\" you can be sure that this is a physical interactions*. *If interaction does not have \"binding\" specified (i*.*e*., *anything else) it may be either physical or functional*". After filtering for physically binding, we then used the combined_score column of 9606.protein.links.v10.5.txt to filter for interactions with score \> = 700. This left us with a total of 11,049 proteins within the PPI network (**[S1 Table](#pgen.1008903.s012){ref-type="supplementary-material"}**).

GWAS catalog {#sec019}
------------

We downloaded the GWAS catalog \[[@pgen.1008903.ref057]\] by downloading the file GWAS_catalog_v1.0.2-associations_e93_r2018-08-28.tsv from [https://www.ebi.ac.uk/GWAS/downloads](https://www.ebi.ac.uk/gwas/downloads). The GWAS catalog \[[@pgen.1008903.ref057]\] contains SNPs associated with diseases and traits collated from the literature. Each SNP is annotated with the closest gene, gathered either from the publication (Reported) or via an automated mapping pipeline implemented within the GWAS catalog (Mapped). The catalog has also been annotated with parent terms, which we obtained by downloading the file gwas-efo-trait-mappings.tsv from <ftp://ftp.ebi.ac.uk/pub/databases/gwas/releases/latest/>. This file maps each of the GWAS studies to Parent Terms by using the shared column of disease traits. We then applied a number of QC filtering cut-offs. We found that some publications were associated with multiple genotyping arrays sometimes with different numbers of SNPS passing QC (captured by the column "PLATFORM (SNPS PASSING QC)"). To ensure we include only 1 genotyping array per publication, we filtered the column "PLATFORM (SNPS PASSING QC)" for the entry with the largest number of SNPS that pass QC in each publication. We found that some loci were associated with multiple p-values, due to different subsets of samples. In order to retain only 1 p-value for each loci, we required that the "P-VALUE (TEXT)" column was an empty string. The "P-VALUE (TEXT)" column contains information describing the context of the p-value (e.g. females, smokers) (<https://www.ebi.ac.uk/gwas/docs/fileheaders>). For instance, if the p-value was computed only in females the entry in the field will be "females", and if the p-value was computed only in smokers the entry in this field will contain "smokers". By requiring that the "P-VALUE (TEXT)" column was an empty STRING, we are only retaining p-values corresponding to the whole dataset.

To extract GWAS hits, we used the "mapped" and "reported" columns to extract out the mapped and reported genes that were also part of the list of 11,049 genes from the PPI network \[[@pgen.1008903.ref056]\]. A small subset of loci had SNP rsids with "x "or ";", which we removed from the analysis. We found some instances where the same gene was linked to multiple loci. This occurs when the gene is very large and multiple GWAS signals are found across the span of the gene. However, this could be problematic in our analyses because multiple p-values will be assigned to the same gene. In order to avoid this problem, we compared the p-values from the different loci containing the same gene and assigned the lowest p-value to that gene. In order to ensure all loci are genome-wide significant, we removed loci where the p-value of the most associated SNP was above the standard genome-wide significance threshold of 5x10^-8^. We noticed that the GWAS catalog contained some loci that contained many genes. Since it is difficult to determine which of these genes is likely to be causal, we only included loci that were annotated with 2 genes at the most.

The catalog also contains ancestry annotations, which we obtained by downloading the file GWAS_catalog-ancestry_r2018-08-28.tsv. In order to separate out studies based on Ancestry; we used the "BROAD ANCESTRAL CATEGORY" from the file: gwas_catalog-ancestry_r2018-08-28.tsv. We only included 5 ancestry categories (European, African American or Afro-Caribbean, Hispanic or Latin American, South Asian and East Asian). After this filtering we were left with 1,381 GWAS studies.

Network randomization {#sec020}
---------------------

We performed network randomization in the same manner as \[[@pgen.1008903.ref027]\]. This method maintains the degree distribution and topology of the network as measured by clustering coefficient. The randomization was done by separating out nodes with the same degree, from nodes with unique degree. We swapped node labels amongst nodes with the same degree, we did this once for each degree, and then repeated it 1000 times. Out of 11,049 nodes, 57 nodes had unique degree, and out of 163,181 edges, 19,392 edges belonged to nodes of unique degree. We grouped nodes with unique degree and performed edge swaps, between different nodes. We performed multiple runs to optimize the number of switching between edges, and found that even after 10 million swaps 3,500 out of 19,392 edges couldn't be randomized. We settled on 100,000 edge swaps for each network.

Since the randomization was performed in 2 stages, we found a small number of edges (100) overlapped between the two steps, and were only counted once in the final network, which led to a small number of nodes differing from the original degree distribution by 1 or 2 nodes. However, when we plotted the degree distribution of the 50,000 randomized networks in gray over-laid with the observed degree distribution of the STRING network in red (**[Fig 1B](#pgen.1008903.g001){ref-type="fig"}**), we found that the degree distribution in the randomized networks matched that of the real STRING network.

To ensure that the topology between the randomized networks is the same as the real network, we computed clustering coefficients. The observed clustering coefficient was 0.47, while the mean clustering coefficient for our 50,000 randomized networks was 0.43 (**[Fig 1B](#pgen.1008903.g001){ref-type="fig"}**). A similar difference was observed in \[[@pgen.1008903.ref027]\], which is the where we obtained our method from.

Identifying studies enriched for PP interactions amongst GWAS hits {#sec021}
------------------------------------------------------------------

To identify studies enriched for PP interactions among GWAS hits, we used the STRING network to count the number of PPI edges. Out of 1,381 studies, we found that 365 studies had at least 2 GWAS hits with at least 1 PPI edge between them. We took the GWAS hits from these 365 studies and counted the PPI edges between them in each of the 50,000 randomized networks. We then counted the number of randomized networks that had PPI edges greater than or equal to the number of PPI edges observed between the GWAS hits in the real STRING network. If the number of PPI edges observed between the GWAS hits in the real STRING network is greater than the number of PPI edges between the same GWAS hits in \> 95% of randomized networks, it was deemed to have more PPI edges than expected by chance.

Replacing GWAS hits with the second closest hit {#sec022}
-----------------------------------------------

We created a bed file with locations of the GWAS hits, then used bedtools \[[@pgen.1008903.ref058]\] 'closest' feature to get the closest gene. In order to maintain the number of GWAS hits in the study, if the first closest gene was already in the list we got the next closest gene. After replacing the GWAS hits with the second closest GWAS hit, we put the GWAS hits on the 50,000 randomized networks to identify studies with excess PPI edges (p \< 0.05). We also counted the number of studies with at least 1 PPI edge between GWAS hits, and after replacing with the second closest GWAS hit, we calculated the proportion of studies with at least 1 PPI edge that have excess PPI edges.

PPI gene detection {#sec023}
------------------

We implemented our method for detecting PPI genes using custom Perl scripts. For each GWAS study we extracted out all the GWAS hits and then compared the GWAS hits to the directly interacting proteins of each protein in the network (**[S1 Table](#pgen.1008903.s012){ref-type="supplementary-material"}**). We then counted the overlap between the GWAS hits for each study and the directly interacting proteins at each node in the network. We then extracted out 3 numbers for every protein node that overlaps with at least 1 GWAS hit. These numbers are: (1) the number of GWAS hits per study (2) the number of directly interacting proteins that are also GWAS hits (3) the degree of the node. We then used custom R scripts to perform a hyper-geometric ratio test to assess whether the level of overlap between GWAS hits and directly interacting proteins is enriched given the total number of GWAS hits in the study, and the degree of the node. We then used the number of nodes that overlap with at least 1 GWAS hit to perform Benjamini-Hochberg multiple testing correction of the raw p-values.

Filter out PPI genes detected by less than 2 GWAS hits {#sec024}
------------------------------------------------------

We then counted the number of GWAS hits that detect each PPI gene and in order to reduce spurious signals, we removed PPI genes that only directly interact with 1 GWAS hit.

Filtering out PPI genes detected by GWAS hits from the same locus {#sec025}
-----------------------------------------------------------------

In order to ensure that the GWAS hits that detect each PPI gene are from 2 different loci, we computed the genomic distance between GWAS hits that detect each PPI gene, and removed PPI genes that are only detected by GWAS hits within 1MB of each other.

Case study: PPI gene Detection in Breast cancer study (GCST001937) {#sec026}
------------------------------------------------------------------

Here we describe in detail how we detected PPI genes in the breast cancer study (GCST001937). The breast cancer study GCST001937 has 37 GWAS hits extracted from the mapped and reported columns of the GWAS catalog that are also within the 11,049 nodes from our STRING PPI network (**[S2 Table](#pgen.1008903.s013){ref-type="supplementary-material"}**). We compared these 37 GWAS hits to the directly interacting proteins of each of the 11,049 nodes. We found that out of 11,049 nodes only 805 nodes have at least 1 direct PP interaction with at least 1 of the 37 GWAS hits. We computed a hyper-geometric ratio test at each of these 805 nodes, using the degree, number of overlaps between directly interacting proteins and GWAS hits and number of GWAS hits in the study (37) as input. Then used the number of nodes with at least 1 PP interaction (n = 805) for Benjamini-Hochberg correction. For example, *BRCA1* has a degree of 152 and it overlaps with 5 of the 37 GWAS hits, and after computing a hyper-geometric ratio test has a raw p-value (p \< 0.00014), and after Benjamini-Hochberg correction it has a p \< 0.026. We used a Benjamini Hochberg corrected p-value cut-off of 0.05, to identify PPI genes. In order to reduce spurious signals, we then removed PPI genes that only overlap with 1 GWAS hit (see "Filter out PPI genes detected by less than 2 GWAS hits" above). In order to ensure that the GWAS hits were not all coming from the same loci, we then computed the distance between the breast cancer GWAS hits and removed PPI genes that were detected by GWAS hits that are all within 1MB of each other (see "Filtering out PPI genes detected by GWAS hits from the same locus" above).

Degree distribution of PPI genes versus the rest of the network--Violin plot {#sec027}
----------------------------------------------------------------------------

We extracted the degree of the PPI genes and compared them to the degree of the rest of the network (**[S9 Fig](#pgen.1008903.s009){ref-type="supplementary-material"}**), and plotted these distributions on a violin plot and performed a Kolmogorov--Smirnov test to determine if the 2 distributions are different.

Visualization of disease networks {#sec028}
---------------------------------

We used custom Perl scripts and the software Gephi version 0.9.2 \[[@pgen.1008903.ref059]\], to visualize networks using the force directed 'Fruchterman Reingold' layout algorithm \[[@pgen.1008903.ref060]\].

Parent term analysis {#sec029}
--------------------

We used GWAS catalog provided parent term annotations to merge GWAS hits with the same parent term among 1000 European Ancestry GWAS studies (**[S2 Table](#pgen.1008903.s013){ref-type="supplementary-material"}**).

Parent terms enriched PPI between GWAS hits {#sec030}
-------------------------------------------

In order to identify parent terms whose GWAS hits have excess PPI edges, we counted the number of PPI edges between the GWAS hits on the STRING network, and the number of PPI edges between GWAS hits on 50,000 randomized networks. Parent terms containing PPI edges between GWAS hits observed in less than 5% of randomized networks, were deemed to have more PPI between GWAS hits than expected by chance.

PPI gene detection in Parent Terms {#sec031}
----------------------------------

We compared the merged GWAS hits in each parent term to the directly interacting proteins of each node within the STRING network, to compute the overlap between GWAS hits and directly interacting proteins. We extracted out 3 numbers for every protein node that overlaps with at least 1 GWAS hit: (1) the number of GWAS hits per study (2) the number of directly interacting proteins that are also GWAS hits (3) the degree of the node. We then used custom R scripts to perform a hyper-geometric ratio test to assess whether the level of overlap between GWAS hits and directly interacting proteins is enriched given the total number of GWAS hits in the study, and the degree of the node. We then used the number of nodes that overlap with at least 1 GWAS hit to perform Benjamini-Hochberg multiple testing correction of the raw p-values. Nodes with Benjamini Hochberg corrected p-values \< 0.05 were deemed parent term PPI genes. Similar to the PPI gene detection method for individual GWAS studies, in order to reduce spurious signal, we also filter out PPI genes detected by less than 2 GWAS hits (see "Filter out PPI genes detected by less than 2 GWAS hits" above), and filter out PPI genes detected by GWAS hits that are all from the same locus within 1MB of each other (see "Filtering out PPI genes detected by GWAS hits from the same locus" above).

Classifying PPI genes as PPI-GWAS or PPI only {#sec032}
---------------------------------------------

PPI genes that are also GWAS hits are PPI-GWAS while the rest are PPI only. Any GWAS hits without a PPI gene are GWAS only.

PPI-GWAS P-value ranks {#sec033}
----------------------

Out of all GWAS studies we detected PPI genes in that have at least 1 PPI-GWAS, we extracted the GWAS catalog provided p-values for all GWAS hits in the study. We then compared the rank of the p-value of each GWAS hit to the total number of GWAS hits in the study to compute a rank fraction (rank/number of GWAS hits in the study). Then compared the rank fraction distribution of all GWAS hits to the rank fraction distribution of PPI-GWAS. To compute enrichment, we counted the number of PPI-GWAS with p-values ranked within the top 10% and top 25% and compared this to the number of total GWAS hits ranked within the top 10% and top 25%, and used Fisher's Exact Test to compute statistical significance.

Clinvar {#sec034}
-------

We used the methods outlined in the blog [https://davetang.org/muse/2017/01/30/exac-allele-frequency-pathogenic-Clinvar-variants/](https://davetang.org/muse/2017/01/30/exac-allele-frequency-pathogenic-clinvar-variants/). Our aim was to extract out pathogenic Clinvar variants. We downloaded the Clinvar data with the file: <http://ftp.ncbi.nlm.nih.gov/pub/Clinvar/vcf_GRCh37/Clinvar_20180603.vcf.gz>, and found that some of the Clinvar variants contained multiple annotations, so we wrote a custom Perl script to extract out only the Clinvar variants with a single annotation. Then from these we extracted out only the Clinvar variants that were annotated as pathogenic (**[S4 Table](#pgen.1008903.s015){ref-type="supplementary-material"}**), and are also within our network (**[S1 Table](#pgen.1008903.s012){ref-type="supplementary-material"}**).

Overlap between Clinvar pathogenic variant containing genes and PPI genes {#sec035}
-------------------------------------------------------------------------

We wrote custom Perl scripts to count the number of PPI genes that also contain Clinvar pathogenic variants. We then compared the proportions of PPI genes in PPI only, PPI-GWAS, GWAS only and all 11,049 proteins in the network. We did this for both the PPI genes detected from the individual GWAS studies and the PPI genes detected from the 12 parent terms. We computed statistical significance using a Fisher's Exact Test.

Pathway enrichment of PPI genes containing Clinvar pathogenic variants {#sec036}
----------------------------------------------------------------------

For each parent term, we extracted out the genes with Clinvar pathogenic variants, then compared these to all genes (n = 11,049) to see if any pathways were enriched. We used the Msigdb 6.2 pathway database \[[@pgen.1008903.ref061]\] and applied Fisher's Exact Test to compute statistical significance and applied Benjamini-Hochberg multiple testing correction.

Oncokb {#sec037}
------

We navigated to the website (<https://www.oncokb.org/>) and downloaded the genes from levels 1--4, and then filtered these genes for those that are within our list of 11,049 nodes. We then compared the proportion of Oncokb genes in cancer parent term GWAS hits and PPI genes and somatically mutated genes and PPI genes and also made comparisons to all the nodes in the network (n = 11,049), and computed statistical significance using a Fisher's Exact Test.

Therapeutic Targets Database {#sec038}
----------------------------

We navigated to the website (<http://db.idrblab.net/ttd/full-data-download>), then navigated to 'Target to disease mapping with ICD identifiers', and parsed the downloaded file for disease entries that contain 'cancer', 'tumor' or 'Metastatic'. Then we used the uniprot ID mapping feature (<https://www.uniprot.org/uploadlists/>), to map the uniprot ids to gene names, then we filtered these genes for those that are within our list of 11,049 genes, and were left with 207 genes. We then compared these 207 genes to the PPI only, PPI-GWAS, GWAS only lists within the cancer parent term and PPI only, PPI-Somatically mutated, and Somatically Mutated lists, and used a Fisher's Exact Test to assess significance.

Cosmic {#sec039}
------

We navigated to the website (<https://cancer.sanger.ac.uk/cosmic>) and navigated to 'Cancer Gene Census' \[[@pgen.1008903.ref052]\] and extracted only tier1 genes, then separated these out into Germline and Somatic, we then filtered these for those within our list of 11,049 nodes. We compared these genes to Cancer Parent Term GWAS hits and PPI genes, and Somatically Mutated genes and Somatically mutated PPI genes and assessed enrichment with a Fisher's Exact Test.

Clustering of Cancer Parent Term PPI Genes {#sec040}
------------------------------------------

We used the STRING network to extract the directly interacting partners of each of the 109 cancer parent term PPI genes. Then we did a pairwise comparison to count the number of directly interacting partners that are shared across each node pair, and then we used the number of shared interacting partners to weight the edge between the 2 nodes. We then used the Fruchterman Reingold force directed layout algorithm \[[@pgen.1008903.ref060]\] within Gephi \[[@pgen.1008903.ref059]\] to visualize the network (**[S6 Fig](#pgen.1008903.s006){ref-type="supplementary-material"}**).

Pathways enriched in the Cancer Parent Term PPI Genes {#sec041}
-----------------------------------------------------

We compared these 78 PPI only cancer parent term PPI genes to the total list of 11,049 nodes in the network, and estimated enriched pathways using the Msigdb pathway database version 6.2 \[[@pgen.1008903.ref061]\] which contains \>17,000 pathways. We assessed enrichment with a Fisher's Exact Test, and used the Benjamini-Hochberg procedure to correct for multiple testing.

Assessing whether somatically mutated cancer genes are enriched for PPI {#sec042}
-----------------------------------------------------------------------

We counted the number of PPI edges between the 218 somatically mutated cancer genes on the STRING network, then compared this to the number of PPI edges between the same 218 somatically mutated cancer genes on 50,000 randomized networks. In order to compute a p-value we computed what proportion of the 50,000 randomized networks, have more PPI edges between the 218 somatically mutated cancer genes than is observed in the real STRING network.

218 somatic genes -\>        on STRING network -\>        \# of PPI between somatic genes = 495

218 somatic genes -\>        Randomized network1 -\>        \# of PPI between somatic genes = 278

218 somatic genes -\>        Randomized network2-\>        \# of PPI between somatic genes = 300

                                Randomized network3

                                Randomized network4

                                Randomized network5

                                Randomized network6

                                Randomized Network 50,000

Detecting PPI genes from somatically mutated cancer genes {#sec043}
---------------------------------------------------------

To calculate PPI genes, we used the same hyper-geometric ratio test based method as above, but instead of GWAS hits, we used the 218 somatically mutated cancer genes. We compared all 218 somatically mutated cancer genes to each node in the STRING PPI network, and counted the number of directly interacting proteins at each node that overlap with the 218 somatically mutated cancer genes. We assessed enrichment by computing a hyper-geometric ratio test at each node using (1) the number of somatically mutated cancer genes that overlap with the direct PPI interactions (2) the degree of the node (3) and the total number of somatically mutated cancer genes (n = 218). We used the nodes with at least 1 PPI interaction with the 218 somatically mutated cancer genes to do Benjamini-Hochberg multiple testing correction, and deemed nodes with adjusted p-value \< 0.05 to be somatically mutated PPI genes. Similar to the core gene detection method for individual GWAS studies, in order to reduce spurious signal, we also filtered out PPI genes detected by less than 2 somatically mutated cancer genes (see "Filter out PPI genes detected by less than 2 GWAS hits" above), and filtered out PPI genes detected by somatically mutated cancer genes that are all from the same locus(see "Filtering out PPI genes detected by GWAS hits from the same locus" above).

Comparison of different interaction types {#sec044}
-----------------------------------------

In this manuscript we only considered physically binding protein interactions, from the STRING network, we did this by requiring that the 'mode' column of the 9606.protein.actions.v10.5.txt was set to 'binding'. However, the STRING network contains other interaction types. We extracted the other interaction types setting the "mode" field to 'reaction', 'catalysis', 'activation', 'inhibition', 'ptmod' (post translational modification) and 'expression'. We then built networks using the entries from these other interaction types. We also built a co-expression network by extracting out the 10^th^ column named 'coexpression' from the file 9606.protein.links.full.v11.0.txt, however due to limited number of nodes we did not filter the co-expression nodes by score.

In order to facilitate comparison, we filtered the nodes from the 8 different interaction networks for the11,049 nodes within our "binding" network, and then detected PPI genes using the 403 GWAS hits from the Cancer parent term (European ancestry, see **[S2 Table](#pgen.1008903.s013){ref-type="supplementary-material"}**). We then compared across different networks by assessing whether *TP53* was detected as a PPI gene, whether there was enrichment for Clinvar pathogenic variants and whether there was enrichment for Oncokb drug targets.

Supporting information {#sec045}
======================

###### Distribution of scores across STRING network.

\(A\) This figure shows the distribution of scores within the STRING PPI network. The scores ranged from 150--999, with a mean of 277.65. We restricted our analyses to PPI interactions with score \> = 700, representing 6% of all PP interactions in the network. The red vertical line represents the score cut-off of 700 we chose for our analysis. (B) Schematic showing that the observed number of PPI among GWAS hits in the STRING network tends to be higher than the number of PPI among GWAS hits in randomized networks.

(TIF)

###### 

Click here for additional data file.

###### Relationship between number of GWAS hits and excess PPI.

\(A\) Distribution of GWAS hits amongst studies with at least 1 PPI edge on STRING, and studies with no PPI edge between GWAS hits. (B) The proportion of studies that have at least 1 PPI edge at each number of GWAS hits. This plot demonstrates that at low GWAS hits the likelihood of having at least 1 PPI edge between the GWAS hits is low, but as the number of GWAS hits increases the chances of having at least 1 PPI edge between the GWAS hits increases. (C) Distribution of GWAS hits amongst studies with excess PPI edges between GWAS hits and amongst studies with no excess in PPI edges between GWAS hits. (D) The proportion of studies with excess PPI edges at each number of GWAS hits. Although there is a tendency for studies with low GWAS hits to have no excess in PPI edges, there are many studies with high numbers of GWAS hits that do not have excess PPI edges. (E) In gray is the degree distribution of the whole STRING network, and in red is the degree distribution of GWAS hits within GWAS studies with excess PPI (n = 270).

(TIF)

###### 

Click here for additional data file.

###### Distributions of GWAS hits and PPI genes.

\(A\) Distribution of number GWAS hits in the 343 Individual GWAS studies we detected PPI genes in. (B) Distribution of PPI genes in the 343 individual GWAS studies we detected PPI genes in. (C) Scatter plot of number of GWAS hits in each study compared to the number of PPI genes in each study, showing very little correlation. (D) Distribution of the number of GWAS hits in 12 parent terms that we detect PPI genes in. (E) Distribution of PPI genes in the 12 parent terms that we detect PPI genes in. (F) Scatter plot of the number of GWAS hits in each parent term compared to the number of GWAS hits.

(TIF)

###### 

Click here for additional data file.

###### Example PPI genes.

PPI genes in Morning vs. Evening chronotype, Parkinson's Disease, A1C Measurement and Alzheimer's Disease. The GWAS catalog study accessions are shown within parentheses.

(TIF)

###### 

Click here for additional data file.

###### Analysis of Clinvar pathogenic variants stratified by degree bin.

Individual GWAS studies: after stratifying by degree-bin we found that PPI-GWAS had the highest proportion of Clinvar pathogenic variants across 4 degree bins (statistically significant in 2 bins) consistent with what was observed prior to stratifying by degree. Parent Term analysis: we found that PPI only had a greater proportion than GWAS only in 3 bins, and PPI-GWAS has a greater proportion than GWAS only in 2 bins.

(TIF)

###### 

Click here for additional data file.

###### Cancer parent term PPI genes.

PPI only are shown in yellow while PPI-GWAS are shown in green, and PPI edges are represented as lines. We used the STRING network to extract the directly interacting partners of each of the 109 cancer parent term PPI genes. Then we did a pairwise comparison to count the number of directly interacting partners that are shared across each node pair, and then we used the number of shared interacting partners to weight the edge between the 2 nodes. We then used the Fruchterman Reingold force directed layout algorithm \[[@pgen.1008903.ref060]\] within Gephi \[[@pgen.1008903.ref059]\] to visualize the network.

(TIF)

###### 

Click here for additional data file.

###### Stratifying cancer parent term PPI genes by degree bin.

Similar to the unstratified analysis we found that PPI-GWAS and PPI only were enriched for COSMIC germline variants, and PPI-GWAS was enriched compared to GWAS only in Oncokb drug targets and PPI-GWAS was enriched compared to GWAS only in Therapeutic Targets Database cancer drug targets.

(TIF)

###### 

Click here for additional data file.

###### Excess PPI among somatically mutated cancer genes.

The size of the node corresponds to the degree, and PPI are represented with lines.

(TIF)

###### 

Click here for additional data file.

###### Degree distribution of the PPI genes compared to the rest of the network.

(TIFF)

###### 

Click here for additional data file.

###### Proportion of somatically mutated PPI genes in bins of different degree size.

(TIF)

###### 

Click here for additional data file.

###### Somatically mutated cancer PPI genes stratified by degree bin.

Similar to the unstratified analysis we found that compared to Somatically Mutated, PPI-Somatically mutated was enriched for COSMIC somatic variants, and PPI-Somatically Mutated was enriched compared to Somatically Mutated in Oncokb drug targets.

(TIF)

###### 

Click here for additional data file.

###### The PPI network used in our study.

There are 11,049 unique nodes in this network.

(XLSX)

###### 

Click here for additional data file.

###### List of GWAS hits in each study.

This table shows the study accession, disease trait, parent term, GWAS hit, SNP, Ancestry, whether the study has excess PPI among GWAS hits and whether a candidate gene was detected, from the 1,381 GWAS studies that went into the analysis.

(XLSX)

###### 

Click here for additional data file.

###### List of candidate core genes in the 343 GWAS studies.

This table contains the study accession, the disease trait, the candidate core gene, the GWAS hits that detected the candidate core gene, the raw p-value, adjusted p-value, Ancestry and whether the study had excess PPI edges between GWAS hits, and whether the candidate core genes is PPI only or PPI-GWAS.

(XLSX)

###### 

Click here for additional data file.

###### List of genes within our network that contain Clinvar Pathogenic variants.

(XLSX)

###### 

Click here for additional data file.

###### Rank fractions calculated from GWAS p-values.

Rank fractions calculated from GWAS p-values for GWAS hits and PPI-GWAS from 119 GWAS studies that contain at least 1 PPI-GWAS. This table contains the rank, study accession, GWAS p-value, disease trait, GWAS hit, SNP, whether the GWAS hits is PPI-GWAS or not, the number of GWAS hits in each study and the rank fraction.

(XLSX)

###### 

Click here for additional data file.

###### List of candidate core genes in Parent Terms.

This table contains the Parent Term, candidate core gene, the GWAS hits that detect each candidate core gene, the raw p-value, adjusted p-value, and whether the candidate core gene is PPI only or PPI-GWAS.

(XLSX)

###### 

Click here for additional data file.

###### PPI-GWAS vs. PPI only proportions across Parent Terms.

This table shows the proportion of PPI-GWAS vs. PPI only candidate core genes in each of the 12 parent terms. It shows that Lipid or Lipoprotein measurement has the highest proportion of PPI-GWAS.

(XLSX)

###### 

Click here for additional data file.

###### Enriched pathways across Parent Terms.

Representative examples of disease relevant pathways enriched amongst parent term candidate core genes that contain Clinvar pathogenic variants.

(XLSX)

###### 

Click here for additional data file.

###### List of the different Cancer studies in the Cancer parent term.

This table shows the number and type of the different cancer studies represented in all 142 GWAS studies that correspond to the Cancer parent term. It contains the number of GWAS hits from the cancer study as well as the number of studies from that cancer type. It demonstrates that Prostate Cancer and Breast Cancer are highly represented.

(XLSX)

###### 

Click here for additional data file.

###### Enriched pathways in Cancer Parent Term.

Pathways enriched in the 78 PPI only Cancer Parent Term Candidate Core Genes, compared to the whole network (n = 11,049).

(XLSX)

###### 

Click here for additional data file.

###### List of 95 COSMIC Germline genes that are also within our network.

(XLSX)

###### 

Click here for additional data file.

###### List of 52 Oncokb Cancer drug targets that are also within our network.

(XLSX)

###### 

Click here for additional data file.

###### List of 207 Cancer Drug Targets from the Therapeutic Targets Database, that are also present within our network.

(XLSX)

###### 

Click here for additional data file.

###### List of somatically mutated genes.

This table shows the 218 somatically mutated cancer genes identified in \[[@pgen.1008903.ref055]\].

(XLSX)

###### 

Click here for additional data file.

###### List of candidate core genes detected from somatically mutated cancer genes.

This table shows the candidate core genes that were identified from the 218 somatically mutated genes listed in [S14 Table](#pgen.1008903.s025){ref-type="supplementary-material"}. It contains the Somatically Mutated candidate core gene, the number of PPI edges to the 218 somatically mutated genes, the raw p-value, the adjusted p-value, whether it is PPI only or PPI- Somatically Mutated and the list of Somatically Mutated genes that it overlaps with.

(XLSX)

###### 

Click here for additional data file.

###### List of 472 COSMIC Somatic genes that are also within our network.

(XLSX)

###### 

Click here for additional data file.

###### Candidate core genes predicted across different types of networks.

Candidate core genes predicted using the 403 Cancer parent term GWAS hits across networks built from different interaction types (Reaction, Catalysis, Activation, Inhibition, Ptmod (post-translational modification), expression and coexpression).

(XLSX)

###### 

Click here for additional data file.

We would like to acknowledge Ronglai Shen for helpful discussions regarding the design of some of the statistical tests used in the manuscript, and would like to thank Samuel Zimmerman for helpful feedback on an earlier version of the manuscript.
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Dear Dr Ratnakumar,

Thank you very much for submitting your Research Article entitled \'Protein-Protein interactions uncover 'core genes' within Omnigenic disease networks\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important problem, but raised some substantial concerns about the current manuscript. Based on the reviews, we will not be able to accept this version of the manuscript, but we would be willing to review again a much-revised version. We cannot, of course, promise publication at that time.

Should you decide to revise the manuscript for further consideration here, your revisions should address the specific points made by each reviewer. We will also require a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

If you decide to revise the manuscript for further consideration at PLOS Genetics, please aim to resubmit within the next 60 days, unless it will take extra time to address the concerns of the reviewers, in which case we would appreciate an expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments are included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see our [guidelines](http://journals.plos.org/plosgenetics/s/submission-guidelines#loc-materials-and-methods).

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool.  PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, use the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

We are sorry that we cannot be more positive about your manuscript at this stage. Please do not hesitate to contact us if you have any concerns or questions.

Yours sincerely,

Xuanyao Liu, Ph.D.

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Although the reviewers commented favorably on the general goal and approach of the manuscript, there were significant criticisms that preclude publications. These comments indicate that significant amount of re-analysis is need to make the paper convincing (See comments of reviewer1 and reviewer2). \"Core genes\" or the gene targets that your approach aims to identify need to be carefully defined, and additional analyses need to support your claims on the findings. We would be willing to reconsider the manuscript after it has undergone a major revision that takes into account of the criticisms of the reviewers, with no assurance of acceptance.

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: In this paper, the authors present a method to identify genes which are enriched for protein-protein interactions (ppi) with genes near GWAS loci (or some other list of genes). The authors argue that these represent "core genes" under the omnigenic model. They describe some examples where the identified genes are known to be highly disease-relevant, and they report that their list of genes is enriched for signal according to clinvar and according to pLI.

I tend to think the authors are onto something with this method, but more work is needed before the paper is convincing. In particular, the authors must distinguish between the following claims: (1) genes with high ppi to GWAS-proximal genes, but without GWAS hits themselves (ppi-only genes), are bonafide disease-relevant genes. (2) among GWAS-proximal genes, those with ppi to other GWAS-proximal genes (ppi-gwas genes) are more disease relevant than those without (gwas-only genes). (3) ppi-only genes, in addition to being disease relevant, are even more disease relevant than gwas-only genes.

This is the sequence of claims that is necessary to justify calling the ppi genes "core", implying that they are more important than most GWAS genes, which are presumably peripheral. The authors have provided evidence for (1), but not for (2-3). I have some suggestions for how they could make these comparisons. However, I do not think that acceptance of the paper should be contingent on identifying strong evidence for both these claims (see below).

The ClinVar and pLI comparisons are made between ppi genes (including both ppi-gwas and ppi-only) and all genes. There is also a comparison with "parent" genes, i.e. genes with high ppi to the larger set of parent-term GWAS-proximal hits. Missing is a comparison with gwas-only genes. I would like to see a comparison between ppi-gwas and gwas-only, and between ppi -only and gwas-only. These comparisons could provide some evidence of (2) and (3) respectively. Moreover, are ppi-only genes enriched for heritability, even if thehy do not harbor significant GWAS hits? Are ppi-gwas genes more likely to be among the very most significant genes, compared with gwas-only genes? For each parent category, is the ClinVar enrichment signal concentrated among genes associated with parent-category-related pathologies?

Even if all these analyses are positive, a critical caveat is that many GWAS-proximal genes will not actually be the right gene. (Could it be possible to observe this empirically, by showing that the 2nd closest gene to each GWAS hit is also enriched with ppi to other GWAS-proximal genes and this cannot be explained by proximal genes having shared ppi?) The reason this caveat can affect these analyses is that it is difficult to distinguish between two possibilities: (1) ppi-gwas genes are more likely to have ClinVar phenotypes because they are more important for disease than gwas-only genes, even though the gwas-only genes are also bona fide disease genes; and (2) ppi-gwas genes are more likely to have ClinVar phenotypes because they are more likely to be the true disease gene, whereas gwas-only genes are more likely to be the wrong gene at the locus altogether (but the correct gene, if we knew it, would be just as important as a ppi-gwas gene). I think the authors need to discuss this distinction. I don't see a way that they can realistically rule out possibility 2, but that's ok: their list of genes is interesting under either possibility 1 or possibility 2.

If the suggested analyses are negative, I don't think it should necessarily preclude publication of this paper, but I would think that some re-writing would be needed. At a minimum, "core genes" should be replaced with "GWAS-interacting gene" or some other, less aspirational term. It's still fine to motivate the network analyses using the omnigenic model, and say that your goal is to identify core genes, but if there is evidence that the identified genes are any more "core" than other GWAS genes, then it doesn't seem appropriate to call them "core genes". You can call p53 a core gene in cancer, but it doesn't follow that all the other ppi genes are just as important.

I want to emphasize again that it is still valuable to identify new disease-relevant genes via ppi with other disease genes, even if you aren't claiming that they are all "core" or even enriched for core genes relative to other GWAS genes.

I have some minor comments as well:

1\. I noticed that many HLA genes are detected, and usually they are annotated as "new" even for phenotypes with clear HLA associations. I think there may be some issue at HLA where only one gene is being picked as the GWAS gene, and the others are being called "new" even though this obviously isn't appropriate at this locus. Probably change the "new" criterion to "not within x Kb of the lead SNP", and possibly exclude HLA from all analyses.

2\. The omnigenic model is usually described in terms of gene-regulatory networks, not ppi networks. I don't think this distinction is critical to the model, but maybe the authors could clarify that ppi is only one way that genes can interact, that it is not the type of interaction most people would associate with the omnigenic model, but that it is just as plausible for peripheral gene effects to be mediated by ppi as it is for them to be mediated by gene-regulatory networks. In addition, the authors could either apply their method to some gene-regulatory networks or explain why they have chosen not to do so (I don't actually recommend doing this).

3\. For any genes that you especially highlight in the text (BRCA1, APP, etc), make sure to be clear about whether they are annotated as GWAS genes in your dataset and also about whether they have been implicated by genetic studies that you did not include. I think a main table could be helpful here: for example, the BRCA1 row could contain a p-value using your method, the rank of this p-value out of all genes, a "no" indicating that this gene is not annotated as a cancer gene in your GWAS data set, and a reference for a study about rare variation in BRCA1.

4\. The writing style is idiosyncratic, especially in the methods section. I found it perfectly readable, but it could be good to run this by someone who is a strong writer.

Reviewer \#2: See attachment.

Reviewer \#3: The manuscript by Ratnakumar and colleagues presented results analyzing GWAS associated genes in light of protein-protein interaction (PPI) networks. Their hypothesis is that genes physically interacting with disease-associated genes with high frequencies are candidates of \"core genes\", according to the omni-genetic model of complex trait genetics. Their analysis identified hundreds of putative \"core genes\" across a large set of phenotypes.

While I think some of the results, especially those about cancer, are interesting, I am not convinced that their analysis really sheds light on core genes under the omnigenetic model. Also the overall novelty of the work is questionable to me. Below are specific comments:

Major comments

1\) Core genes have a specific meaning under the omnigenetic model: they are believed to mediate the effects of a potentially large number of genes associated with a complex trait (called \"peripheral genes\"). The omnigenetic paper discusses regulatory influence of perturbation of peripheral genes on core genes, in partiular, as one main mechanism. It seems to me that this paper mis-interprets the concept of core genes. All the analysis are based on the numbers of PPIs: there is no evidence that the genes interacting with other GWAS genes would \"mediate\" their effects on disease risks.

The analysis is more like finding \"hub\" genes in PPI network. There is a large literature on this topic, including some in the context of disease genetics, e.g. 21764832, 21490723, 25915600. It seems to me that none of these papers is properly cited. Given this background, I think the conceptual novelty of the work is quite limited.

2\) In Figure 3d: the authors show that their core genes are more enriched with constrained genes (according to pLI scores). The authors compare pLI distribution of the core genes vs. all genes in the PPI network. I think the core genes are likley to have higher degress than background, so this analysis should control for degree distribution of two gene sets being compared. Otherwise, the results would show \"highly connected\" genes are more likely to have high pLI scores. This would be similar to earlier studies showing hub genes are under stronger evolutionary constraint, but this would have no implications on genetics of diseases.

3\) The results of cancer core gene analysis are interesting. However, the analysis seems somewhat superficial. I would recommend the authors to perform some deeper analysis. For example, they reported \>100 new genes, what are the overepresented biological pathways other than immune genes? Any specific new genes that may provide some new insights on cancer? If one compares across cancer types, are the genes usually found in one cancer type or multiple cancer types?

Minor comments

1\) Figure legends are generally too long and sometimes redundant with the main text.

2\) Lines 336-340: the authors mentioned that lipid traits have the highest proportion of core genes that are also top GWAS hits, and offered the possible explanation that lipid traits may be less polygenic. While this may well be true, I think it is important to consider the power of studies. For studies with large sample sizes (likely the case for lipid traits), it is likely that many \"core\" genes would be found as GWAS hits, so the proportion would be high.

3\) Line 358: should cite Figure 3e instead of 3c.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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\* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. \*

Dear Dr Ratnakumar,

Thank you very much for submitting your Research Article entitled \'Protein-Protein interactions uncover candidate 'core genes' within Omnigenic disease networks\' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. While we cannot make a definite commitment, we will probably accept your paper for publication, if you provide an answer to reviewer 1 on the node degree correction for Clinvar analysis and the drug target analysis, and make changes according to the remaining of the reviewers' comments.

In addition we ask that you:

1\) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2\) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our [archive](http://www.plosgenetics.org/article/browse/volume). If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to <plosgenetics@plos.org>.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our [Submission Checklist](http://journals.plos.org/plosgenetics/s/submit-now#loc-submission-checklist).

While revising your submission, please upload your figure files to the [Preflight Analysis and Conversion Engine](http://pace.apexcovantage.com/) (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as \"data not shown\" or \"unpublished results\" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated [Similarity Check](http://www.crossref.org/crosscheck.html), powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and \'Revise Submission\' in the \'Submissions Needing Revision\' folder.

\[LINK\]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Xuanyao Liu, Ph.D.

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors have provided a thorough response to my comments and suggestions. Following the comments of Reviewer 2, I am now curious whether the Clinvar analysis and the drug target analysis were corrected for node degree. Otherwise, I only have presentation-related comments:

• In the current presentation, it feels like you are assuming your hypothesis is true (that ppi genes are candidate core genes) throughout pages 9-15. I would recommend that in this section, you use the term "ppi genes" instead of "candidate core genes". Then, you could retitle the section starting on page 15 "Clinvar enrichment: ppi genes are candidate core genes." The title for p. 21 could be "Drug target enrichment: ppi genes are candidate core genes", and on p. 22, "Cancer driver enrichment: ...".

• The main figures should be readable without referencing the caption. Currently, many axes are unlabeled, and the titles are inconsistent (Figures 3-5). I would recommend adding axis labels everywhere it is not totally obvious and making all titles describe what is being plotted (rather than delivering the punchline).

• Consider including the finding of no excess GWAS signal at ppi-only genes. This analysis suggests that ppi-only genes would not be detected in GWAS of larger sample size.

• In many places, a long sentence should be split into two sentences. For example, see lines 85-89, 104-109, 202-205, 250-259, 637-640. In a number of places, a comma should be deleted (e.g. lines 637, 644, 139).

Reviewer \#2: I congratulate the authors for successfully incorporating reviewer feedback into the manuscript. My concerns with the text have been satisfied, and I have only minor comments below.

Line 65: "insulin for" rather than "insulin in"

Line 66: BRCA1, as a protein, should not be italicized

Line 69: Technically the experiments still have to be performed. It is more accurate to say "by utilizing publicly available reference datasets."

Line 264: delete the second comma

Line 386-389: Sentence is difficult to make sense of.

Line 473: delete the comma

Line 573-586: I think this could be condensed to provide a simple, short summary.

Line 597-603: I think it suffices to say "We present a new application of GWAS data: identifying core genes as envisioned by the omnigenic model that do not themselves exhibit GWAS signal by consulting physical interactions."

Line 629-631: Sentence should be rewritten.

Line 637: delete first comma.

Line 644-653: I recommend deleting this paragraph. It is not terribly helpful.

Line 666-667: As described earlier, the method does not exactly work on every GWAS -- the GWAS must have enough hits with PPI edges. It would be better to say that this method adds another layer to interpreting GWAS signal.

Lines 897-906: This should be rewritten so say very clearly that candidate core genes within 1 Mb of a GWAS hit are PPI-GWAS hits while the rest are PPI only. Any GWAS hits without a candidate core gene are GWAS-only.

Lines 949-952: Delete.

Lines 1046-1050: Delete.

In general: The omnigenic model is by convention not capitalized

Figure 1c: gene symbol names and axis text too small

Figure 1b step 2: axis text way too small

Figure 3d,e: axis text too small

Figure 4e: axis text too small

Figure 5e: number text too small

Figure 5f: axis text too small

Reviewer \#3: The reviewers have done a good job at addressing my comments. While conceptually related to several papers published in the past, I think the large-scale analysis the authors performed across many GWAS datasets would be a useful resource for the community.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

10.1371/journal.pgen.1008903.r004
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1 Jun 2020

Dear Dr Ratnakumar,

We are pleased to inform you that your manuscript entitled \"Protein-Protein interactions uncover candidate 'core genes' within Omnigenic disease networks\" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you've already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at <plosgenetics@plos.org>.

In the meantime, please log into Editorial Manager at <https://www.editorialmanager.com/pgenetics/>, click the \"Update My Information\" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Xuanyao Liu, Ph.D.

Guest Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

[www.plosgenetics.org](http://www.plosgenetics.org)

Twitter: \@PLOSGenetics

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Comments from the reviewers (if applicable):

The authors have addressed all the comments of the reviewers to their satisfaction. Thank you very much for the effort.

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors have fully addressed my comments.

Reviewer \#2: I commend the authors for their diligence in responding to reviewer comments. My concerns have been fully addressed.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Genetics* [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosgenetics/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Luke O\'Connor

Reviewer \#2: Yes: Evan A Boyle

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Data Deposition**

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the [Dryad Digital Repository](http://www.datadryad.org). As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our [website](http://journals.plos.org/plosgenetics/s/data-availability#loc-recommended-repositories).

The following link will take you to the Dryad record for your article, so you won\'t have to re‐enter its bibliographic information, and can upload your files directly: 

<http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01600R2>

More information about depositing data in Dryad is available at <http://www.datadryad.org/depositing>. If you experience any difficulties in submitting your data, please contact <help@datadryad.org> for support.

Additionally, please be aware that our [data availability policy](http://journals.plos.org/plosgenetics/s/data-availability) requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Press Queries**

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper\'s publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there\'s anything the journal should know or you\'d like more information, please get in touch via <plosgenetics@plos.org>.

10.1371/journal.pgen.1008903.r006
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6 Jul 2020

PGENETICS-D-19-01600R2

Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks

Dear Dr Ratnakumar,

We are pleased to inform you that your manuscript entitled \"Protein-Protein interactions uncover candidate 'core genes' within omnigenic disease networks\" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Matt Lyles

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom

<plosgenetics@plos.org> \| +44 (0) 1223-442823

[plosgenetics.org](http://plosgenetics.org) \| Twitter: \@PLOSGenetics

[^1]: The authors have declared that no competing interests exist.
